Form Bio
Austin, US · Founded 2022 · Delaware corporation · 37 employees on LinkedIn · 5 known investors
Find your way into Form Bio
3,032 people in our graph share verified history with the Form Bio team — schools, employers, funds. One of them is your warm intro.
Form Bio develops AI-driven software and bioinformatics tools for genetic medicine and genome engineering, enabling faster and safer design of gene therapies, protein engineering, and manufacturing optimization.
Also known as Form
Founders & leadership
Form Bio was founded in 2022 by Benjamin Lamm and Andrew Busey.
Board
Investors · 5
Reported raises · per SEC filings
Form D private placements$16M disclosed across 1 round · 2022
▶$16MraisedSep 2022 · 4 investors · BiotechnologyRule 506(b)
- John SpinaleDirector
- Benjamin LammDirector, Promoter
- Andrew BuseyExecutive Officer, Director, Promoter
- Kent WakefordExecutive Officer, Director, Promoter
- Offering amount
- $26.3M
- Amount sold
- $16M
- First sale
- Sep 2022
- Incorporated
- Corporation, Delaware, 2022
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Company profile
researched Aug 2026Form Bio is a software and services company applying artificial intelligence and computational biology to genetic medicine and genome engineering. Its genetic medicine offering centers on FormManufacturing, which bundles two integrated services: FormSightAI, which screens thousands of viral vector designs in silico to prioritize high-performing candidates with the aim of improving yield, reducing contaminants and lowering cost of goods; and FormBatchQC, which provides lot-level analysis of contaminants and batch comparability to support regulatory filings and inspections. Additional applications include genome assembly, genome integrity analysis (assessing full versus partial encapsidated genomes and mapping truncation hotspots to vector maps), and codon optimization using the company's proprietary FORMsight AI model, which optimizes sequences across objectives such as protein expression, manufacturability and safety.
Beyond human therapeutics, Form Bio supports genome engineering programs — including those of Colossal Biosciences — covering CRISPR, base and prime editing design, AI-assisted genotype-to-phenotype analysis, and validation of on-target efficiency and off-target effects via amplicon or whole-genome sequencing. An animal health line addresses gene editing for trait enhancement, population genomics for breeding, integrated genomic and phenotypic data management for disease surveillance and outbreak response (for example avian influenza), and genomic QC and characterization across generations. Listed solution categories include drug substance insights, capsid analysis, bioinformatics analysis, gene editing, AI model development and manufacturing intelligence. The company describes its staff as AI and software engineers, bioinformaticians, molecular and cellular biologists, and drug developers.
Founding story
Form Bio is described as the first spinout from Colossal Biosciences, formed in 2022 to extend Colossal's foundational multi-species genome engineering technology into human genetic medicines. Andrew Busey, a co-founder of Colossal Biosciences with a prior career spanning Mosaic, iChat and Zynga, co-founded Form Bio and served as co-CEO; in a 2023 podcast interview he framed the company as addressing poorly managed data in the biotech industry by combining software with deep-tech domains.
Business model
Form Bio sells software and analytical services to biopharmaceutical and biotechnology organizations, packaging AI-driven design (FormSightAI), batch quality control (FormBatchQC) and bioinformatics/analysis services, along with AI model development, for customer programs.
Traction
Public customer references include Coave Therapeutics, Taysha Gene Therapies and Solid Biosciences, and Colossal Biosciences is cited as relying on Form Bio for genome engineering programs. The company shows a pipeline of partnered programs spanning Duchenne muscular dystrophy, limb girdle muscular dystrophy type 2G and Alzheimer's disease across discovery through clinical stages. Built In Austin lists roughly 50 employees and two offices.
Latest developments
The company's current offering is organized around FormManufacturing, combining FormSightAI vector design screening with FormBatchQC lot-level batch analysis, plus expanded animal health and genome engineering service lines.
▸Full profile — market position, technology, go-to-market, geography, history
Market position
The company positions itself at the intersection of software/AI and deep-tech biology, serving gene therapy developers as well as non-human genome engineering and animal health applications, and is publicly endorsed by academic figures including George Church.
Technology
The platform combines AI/machine-learning models with bioinformatics analysis. Core components include in silico screening of large numbers of vector designs, the proprietary FORMsight AI model for multi-objective codon optimization and identification of codon substitutions, genome assembly and reconstruction pipelines, genome integrity analysis that characterizes encapsidated full versus partial genomes and truncation hotspots, and sequencing-based validation of on-target editing efficiency and off-target effects using amplicon or whole-genome sequencing.
Go-to-market
Gene and cell therapy developers, genome engineering programs, and animal health and breeding organizations. Named users and references include Coave Therapeutics, Taysha Gene Therapies, Solid Biosciences and Colossal Biosciences.
Geography
Two offices in Texas, listed by Built In Austin as headquarters in Dallas with an additional location in Austin; remote roles are also posted.
History
Founded in 2022 as a spinout of Colossal Biosciences, the company was initially positioned around empowering scientists with data, computing power and collaboration tools. As of a May 2023 interview, Andrew Busey was co-founder and co-CEO. The current site presents Michelle Chen, PhD as President and CEO, alongside a leadership team covering technology, AI, synthetic biology, genetic medicine, business development, marketing and HR, and the product framing has moved toward AI-driven genetic medicine design and manufacturing services.
Compiled by commissioned research from 7 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Founder mafia
3 people who came through Form Bio went on to found or lead other companies.
Competitors · 3
by search overlap
Companies competing with Form Bio for the same Google search keywords, organic and paid, via search-intersection analysis.
Timeline · 1
launches, deals, and filingsForm Bio was established as the first spinout from Colossal Biosciences, extending multi-species genome engineering technology toward human genetic medicines.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
Legal entities · 1
corporate structure▸Research sources · 7
primary sources listed
- Form Bioformbio.com · web
7 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Form Bio do?
- Form Bio applies AI and bioinformatics to genetic medicine design, manufacturing QC and genome engineering.
- Who founded Form Bio?
- Form Bio was founded by Benjamin Lamm, Andrew Busey in 2022.
- Who are Form Bio's investors?
- Form Bio's investors include Bold Capital Partners, Breyer Capital, Carnrite Ventures, Draper Associates, JAZZ Venture Partners.
- How much funding has Form Bio raised?
- Form Bio has disclosed $16M raised across 1 round.
- Where is Form Bio headquartered?
- Form Bio is headquartered in Austin, US.